Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Part of paid clinical trials in East Windsor, New Jersey.

Sponsor
Psoriasis Treatment Center of Central New Jersey
Study ID
NCT03827876
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Enstilar 0.005%-0.064% Topical Foam — DRUG
    Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

Study Details

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Key Dates

Start date
Jan 16, 2019
Status verified
Jan 2019
Primary completion
Sep 15, 2019
Completion
Dec 15, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open Label Enstilar
    once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

Primary Outcome Measure

PGA x BSA improvement [ Time Frame: 16 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Psoriasis Treatment Center of Central New JerseyEast WindsorNew Jersey08520
Elise Nelson
[email protected]
609-443-4500
Jerry Bagel, MD (PRINCIPAL_INVESTIGATOR)
Brian Keegan, MD, PhD (SUB_INVESTIGATOR)
David Nieves, MD (SUB_INVESTIGATOR)
Alexa Hetzel, PA-C (SUB_INVESTIGATOR)

Find similar trials in East Windsor, NJ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Psoriasis Treatment Center of Central New Jersey· East Windsor, NJ

Related Studies